Private-credit & direct-lending funds

Kreos Capital

BlackRock's venture and growth debt desk, lending €2m to over €100m to venture-backed technology and healthcare companies across Europe and Israel from a London team that has run the strategy since 1998.

Considering finance for your business? Discuss the lender options.

Fig. 01

Published band £1.7m to £85m, against the other 59 private-credit and direct-lending funds.

Kreos Capital publishes £1.7m to £85m.Kreos Capital's published facility band, £1.7m to £85m, drawn on a logarithmic axis from £100k to £100m against the £3m to £15m band and the shaded field of the other 59 private-credit and direct-lending funds, which is taller where more of them publish a band covering that size.£3–15m£1.7m£85m£100k£1m£10m£100m
Published facility bands: Kreos Capital against the other private-credit and direct-lending funds in this directory.
LenderPublished band
Kreos Capital£1.7m to £85m
The other private-credit and direct-lending funds28 of 59 publish a band; at the field's peak 23 of them cover the same facility size
The band this directory reads for£3m to £15m

The shaded field is the other 59 private-credit and direct-lending funds in this directory, taller where more of them publish a band covering that size. Kreos Capital’s bar is its own published range. A band is what a lender states it will do, not what it will do on a given credit.

What they do

Kreos Capital is the venture and growth debt business of BlackRock, which bought it in August 2023 and moved the whole team onto its Private Markets platform to run the same growth debt strategy. BlackRock did not disclose the price; trade press put it at around $400m. Kreos has lent to technology and healthcare companies across Europe and Israel since 1998, and its page gives figures as of the third quarter of 2025: more than €7bn committed across over 830 transactions to more than 640 companies, 8 funds in operation and more than €800m invested a year. Money comes from committed fund capital raised from institutional investors rather than from deposits, and the seventh fund, Kreos Capital VII, closed at €1.25bn in 2024 against a €1.2bn target. The product is growth debt in several forms: venture and growth term loans, growth loans, convertible debt and structured facilities, drawn beside or after an equity round to extend runway, fund an acquisition or pay for capital expenditure. The site describes support at every stage, from entry-level growth and mid-stage development through late stage, pre-IPO and exit funding to publicly listed growth funding. The London team, 45 people at the acquisition, is led by seven partners and keeps a presence in Sweden and Israel.

Who they lend to

Borrowers are high-growth technology and healthcare companies that already carry venture or growth-equity backing, since Kreos describes itself as a partner to both management teams and equity sponsors. In technology it has invested across fintech, enterprise software, cybersecurity, semiconductors, digital marketing and AI; in healthcare across drug and treatment development, medical products and devices, and healthcare tech. Most borrowers are pre-profit, so there is no turnover or EBITDA band and, on third-party accounts, no minimum net worth, current ratio or debt-to-equity test. Transactions run from €2m to over €100m, about £1.7m to £85m, and the strategy reaches from early growth to pre-IPO and listed companies. Its pre-acquisition site listed adult, gambling, weapons and crypto as exclusions, together with pre-revenue companies without venture backing; the BlackRock page prints no exclusion list. Geography is Europe and Israel, with investments in 22 countries and the UK served from the London headquarters. An owner-managed company with no institutional equity sits outside the profile.

How they structure a facility

The instrument is a term loan sized to the equity story rather than to earnings: growth debt, venture debt, convertible debt or a structured facility, drawn alongside or after a round. Sizing rests on revenue growth, recurring revenue, cash runway and the size and backers of the round, so leverage is never quoted as a multiple of EBITDA. Third-party reviews describe security as senior over all assets, intellectual property included, with warrants attached as an equity kicker on top of the coupon, and they record prepayment terms and administration fees. Kreos itself publishes none of this on its BlackRock page, and it publishes no pricing, no tenor, no amortisation profile and no covenant package. Nor does the page state a position on personal guarantees either way. What it does say is that facilities are built to match the changing needs of high-growth companies through the cycle, with capital from institutional investors behind them, and that the preferred relationship is a long-term one shared with the equity sponsor.

Published terms

Pricing
Not published
Published by 1 of 60
Speed to terms
Not published
Published by 8 of 60
Sponsored or sponsorless
Venture or growth-equity-backed companies; lends alongside or after equity rounds and describes equity sponsors and management teams as its partners
Where they lend
Europe and Israel, with investments in 22 countries; headquartered in London with a presence in Sweden and Israel
How they decide
In-house Kreos investment team within BlackRock European Private Debt; relationship + VC-ecosystem origination; institutional credit governance; delegated authority not published
Covenants
Not published
Published by 15 of 60
Search funds and ETA
No published route for search-fund or first-time acquirer borrowers
Minimum loan
€2m, about £1.7m, per BlackRock's recruitment page for the team
Maximum loan
€100m and above, about £85m at the top of the stated range

As published by the lender and last reviewed October 2026. Terms quoted on a deal are set by the credit, not by a published band.

How a deal reaches them

Origination runs through the venture ecosystem that funds its borrowers: Kreos describes close working relationships with equity sponsor partners and management teams, and repeat business across a portfolio of more than 550 companies. No broker channel or online application is published; a company or its sponsor approaches the London team, which covers the UK, or the offices in Sweden and Israel. Credit decisions sit with the Kreos investment team inside BlackRock's European Private Debt platform, where the pre-acquisition leadership still runs the strategy under BlackRock governance. Kreos publishes no delegated authority, no timetable to terms and no application checklist. What it underwrites is the equity round and the investors behind it, revenue growth, recurring revenue and the runway the debt will extend; the analyst role BlackRock advertised in October 2026 describes underwriting and execution across every stage of the investment lifecycle.

Where they fit in a lower-mid-market raise

A venture-backed technology or healthcare company raising £3m to £15m beside or after an equity round, to stretch runway, buy a competitor or fund capital expenditure, is the shape Kreos is built for. Its €2m floor, about £1.7m, sits below the band, and a ceiling of €100m or more means the lender need not be replaced as the company grows through later rounds, pre-IPO funding and a listing. The argument for it over a younger fund is depth: a team in place since 1998, more than 830 transactions through several cycles, and BlackRock's platform behind it. Among lenders that underwrite recurring revenue and runway rather than earnings, it sits with Claret, Columbia Lake Partners, Salica and Palatine Growth Credit, and it is unusual among them in treating healthcare, including drug development and medical devices, as a core sector rather than an exception.

Where they are not the fit

Kreos is the wrong call for a company without venture or growth-equity backing, including a profitable owner-managed business or a search-fund buyer of a traditional SME, for which no route is published. Anything outside technology and healthcare is outside the mandate, and the pre-acquisition exclusions of adult, gambling, weapons and crypto stand until the site says otherwise. A borrower whose case rests on EBITDA and asset cover rather than on growth and recurring revenue will not fit the sizing. Warrants and fees sit on top of the coupon, so the all-in cost is above the headline rate, and none of it is published, so terms come only from a conversation. Nothing on the page says how long a decision takes.

What rules a deal out

Stated limits, taken from Kreos Capital’s own published criteria. A limit is where a lender starts from, not where it always ends: several of these move on a strong enough credit.

  • Outside technology & healthcare off-piste
  • VC/growth-equity-backed profile expected
  • €2m (~£1.7m) practical floor
  • Sized on growth/ARR not EBITDA
  • No appetite in adult, crypto, gambling, non-vc-backed early-stage or weapons

How they sit against the category

  • Its published ceiling of £85m is among the 6 highest of the 60 private-credit funds here.
  • It opens lower than almost all of them, at £1.7m.
  • Like 59 of the 60, it publishes no indicative price; a margin comes from a conversation, not a page.

Counted across the 60 private-credit & direct-lending funds in this directory, on what each one publishes. What a lender discloses and what it will do are different things.

Recent activity on the public record

In June 2023, BlackRock announced a definitive agreement to acquire Kreos, then a 45-person London team that had committed €5.2bn across more than 750 transactions in 19 countries. In August 2023, the acquisition closed and the team joined BlackRock's European Private Debt platform, with the existing leadership responsible for the strategy. In 2024, Kreos Capital VII reached a final close of €1.25bn against a €1.2bn target, 40% larger than its predecessor, and joined BlackRock's EMEA debt platform, targeting €2.4bn to €2.5bn of commitments across 90 to 100 companies. In June 2025, Kreos took part in the McMakler Series D-II round. In October 2026, BlackRock advertised a London analyst role on the venture and growth debt team, describing transactions of €2m to over €100m.

Fig. 02

7 dated items, 2023 to 2026, numbered as listed below.

Kreos Capital: 7 dated items on the public record, 2023 to 2026.1. Jun 2023; 2. Aug 2023; 3. Aug 2023; 4. 2024; 5. 2024; 6. 2025; 7. Oct 20262023202420252026202701020304050607
Kreos Capital: dated items on the public record, in order.
No.DateItem
01Jun 2023BlackRock and Kreos announced a definitive acquisition agreement; Kreos had then committed €5.2bn across more than 750 transactions in 19 countries.
02Aug 2023BlackRock completed ~$400m acquisition of Kreos; all employees to BlackRock Private Markets, same growth-debt strategy.
03Aug 2023BlackRock completed its acquisition of Kreos; the 45-person London team joined BlackRock's European Private Debt platform with the existing leadership in charge of the strategy.
042024Kreos Capital VII final close €1.25bn (vs €1.2bn target; 40% larger than predecessor); largest EMEA venture & growth-debt fund; joined BlackRock EMEA debt platform (Funds Europe / Private Equity Wire.
052024Kreos Capital VII reached a final close of €1.25bn against a €1.2bn target, 40% larger than its predecessor, and joined BlackRock's EMEA debt platform.
062025Figures as of the third quarter show more than €7bn committed across over 830 transactions to more than 640 companies, 8 funds in operation and more than €800m invested a year.
07Oct 2026BlackRock advertised a London analyst role on its venture and growth debt team, stating that transactions range from €2m to over €100m.

On the record

  • June 2023: BlackRock and Kreos announced a definitive acquisition agreement; Kreos had then committed €5.2bn across more than 750 transactions in 19 countries.

    ir.blackrock.com

  • August 2023: BlackRock completed its acquisition of Kreos; the 45-person London team joined BlackRock's European Private Debt platform with the existing leadership in charge of the strategy.

    ir.blackrock.com

  • August 2023: BlackRock completed ~$400m acquisition of Kreos; all employees to BlackRock Private Markets, same growth-debt strategy.

  • 2024: Kreos Capital VII reached a final close of €1.25bn against a €1.2bn target, 40% larger than its predecessor, and joined BlackRock's EMEA debt platform.

    funds-europe.com

  • 2024: Kreos Capital VII final close €1.25bn (vs €1.2bn target; 40% larger than predecessor); largest EMEA venture & growth-debt fund; joined BlackRock EMEA debt platform (Funds Europe / Private Equity Wire.

  • 2025: Figures as of the third quarter show more than €7bn committed across over 830 transactions to more than 640 companies, 8 funds in operation and more than €800m invested a year.

    blackrock.com

  • October 2026: BlackRock advertised a London analyst role on its venture and growth debt team, stating that transactions range from €2m to over €100m.

    careers.blackrock.com

Questions this page answers

How much will Kreos Capital lend to a company?

BlackRock's recruitment page for the team says transactions range from €2m to over €100m, and the Kreos page says it invests more than €800m a year. No sterling band is published; the floor is roughly £1.7m and the top of the stated range about £85m.

As published at careers.blackrock.com

Who owns Kreos Capital now?

BlackRock, Inc., which completed its acquisition on 2 August 2023. The Kreos employees all moved onto BlackRock's Private Markets platform, where they run the same growth debt strategy, and the Kreos leadership kept responsibility for executing the existing investment strategies.

As published at ir.blackrock.com

Which sectors does Kreos Capital lend to?

Technology and healthcare only. In technology it names fintech, enterprise software, cybersecurity, semiconductors, digital marketing and AI; in healthcare, drug and treatment development, medical products and devices, and healthcare tech.

As published at blackrock.com

Does Kreos Capital lend in the UK or only in continental Europe?

Both. Kreos is headquartered in London, with a further presence in Sweden and Israel, and says it has invested in 22 countries across Europe and Israel.

As published at blackrock.com

What stage does a company need to be at for Kreos Capital?

The site describes support through every stage of the growth life cycle, from entry-level growth and mid-stage development, through late stage and pre-IPO or exit funding, to publicly listed growth funding. It works alongside equity sponsors, so institutional backing is the norm.

As published at blackrock.com

Does Kreos Capital take a personal guarantee?

Not stated. The BlackRock page publishes no security, covenant or guarantee terms; it describes debt facilities matched to the needs of high-growth companies and a working relationship with equity sponsors and management teams.

As published at blackrock.com

Does Kreos Capital lend to companies without a private-equity sponsor?

Not on the published evidence. Kreos Capital lends alongside institutional equity or sponsor backing rather than to unbacked borrowers.

Sources: kreoscapital.com · funds-europe.com · privateequitywire.co.uk · blackrock.com

Terms used on this page: Sponsor · Amortisation

This profile is a curated reference note drawn from public sources, not financial advice or a recommendation. Appetite and terms change; a lender's fit for a given credit is established by approaching it, not inferred from a page.

SolonCorporate Finance

Independent debt advisory for UK lower-mid-market companies.

Discuss your financing

© 2026 Solon Corporate Finance Ltd. Registered in England & Wales, company number 17320026.

Registered office: 124 City Road, London EC1V 2NX.

Solon Corporate Finance Ltd advises on and arranges commercial debt facilities for UK companies. Arranging and advising on plain commercial lending to corporate borrowers is not a regulated activity under FSMA, and Solon is not authorised or regulated by the Financial Conduct Authority.